Masimo Gets CE Mark For ANI Module, Enhances Root Platform

Masimo Corporation (NASDAQ:MASI) and Mdoloris Medical Systems recently unveiled the CE marking of the Mdoloris Analgesia Nociception Index (ANI) module for the Masimo Root Patient Monitoring and Connectivity Hub. This marks the first commercially available result of Masimo Open Connect (MOC) third-party partnership between Masimo and Mdoloris.

It is to be noted here that ANI on Masimo Root has not received 510(k) clearance and is not available for sale in the United States. However, it has been cleared for sale in the European Union (EU).

A Few Words about ANI

According to the British Journal of Anaesthesia, the ANI is a 0-100 index derived from heart rate variability (HRV) that offers a continuous measurement of the parasympathetic tone as a surrogate for the analgesia/nociception balance. In this regard, high values correspond to maximum parasympathetic activity (analgesia) and low values correspond to sympathetic activation (nociception).

Masimo’s Root Platform at a Glance

Notably, Masimo’s Root platform is a very powerful, expandable patient monitoring and connectivity hub that brings together a range of technologies, devices, and systems to offer multimodal monitoring and connectivity solutions in a single, clinician-centric platform.

Further, Root provides expandable measurement capability through plug-and-play MOC-9 modules. The modules help Root to expand capabilities with additional Masimo and third-party measurement technologies. This in turn helps clinicians to connect the most relevant solutions for each patient.

With the introduction of ANI, Masimo strives to strengthen its Root platform. Together with MOC, the platform can accelerate the patient monitoring innovation cycle, lower the cost of the same and extend the useful life of the equipment that hospitals invest in.

Patient Monitoring in Focus

Masimo is touted to be the most innovative company in the patient monitoring space. In fact, with the consistent expansion of its abilities, the company’s Root platform is set to become one of the most powerful bedside platforms.

According to report by Research and Markets, the global market for patient monitoring devices will witness a CAGR of 8.2% to nearly $30.7 billion by 2022. Growing economy, rise in the prevalence of chronic diseases and increasing adoption of cost effective remote patient monitoring devices will drive growth in this market.

Masimo remains committed toward enhancing patient monitoring and its efforts reflect the same. In non-invasive patient monitoring, the company’s Patient SafetyNet, Rainbow acoustic monitoring, SedLine brain function monitoring, Capnography and gas monitoring deserve a mention.
Additionally, Masimo’s program to improve opioid safety via innovative monitoring technology for both post-surgical wards and home use deserves mention in this regard.

Stocks that Warrant a Look

Investors interested in other stocks from the broader medical space might consider Edwards Lifesciences Corporation (NYSE:EW) , Fluidigm Corporation (NASDAQ:FLDM) and STERIS plc (NYSE:STE) .

Edwards Lifesciences has delivered positive surprises in three of the last four quarters with an average beat of 5.8%.

Fluidigm has delivered positive surprises in two of the last four quarters with an average beat of 28.6%.

STERIS has delivered positive surprises in three of the last four quarters with an average beat of 1.4%.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>